Profile data is unavailable for this security.
About the company
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. The Company combines image-guided local beta radiation and targeted drug delivery approaches. The Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). Its radiotherapeutic candidate, rhenium (186Re) obisbemeda, is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC). The Company’s Rhenium (186Re) obisbemeda, a novel injectable radiotherapy designed to deliver targeted, high dose radiation directly into GBM tumors. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers.
- Revenue in USD (TTM)4.91m
- Net income in USD-13.32m
- Incorporated1997
- Employees20.00
- LocationPlus Therapeutics Inc4200 Marathon Blvd Ste 200AUSTIN 78756-3433United StatesUSA
- Phone+1 (858) 458-0900
- Fax+1 (302) 636-5454
- Websitehttp://www.plustherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Combigene AB | 476.10k | -3.06m | 6.34m | 8.00 | -- | 0.6342 | -- | 13.32 | -1.80 | -1.80 | 0.28 | 5.88 | 0.0398 | -- | 2.63 | 693,015.00 | -25.58 | -13.00 | -26.56 | -14.58 | -- | -- | -643.32 | -58.77 | -- | -- | 0.00 | -- | -79.23 | 268.58 | -479.27 | -- | -24.02 | -- |
| ViroGates A/S | 748.74k | -1.62m | 6.38m | 10.00 | -- | 2.80 | -- | 8.52 | -6.12 | -6.12 | 1.61 | 2.64 | 0.2653 | 0.2654 | 3.15 | 558,300.00 | -57.47 | -46.58 | -63.01 | -52.09 | 78.83 | 77.91 | -216.66 | -238.01 | 8.56 | -23.89 | 0.2376 | -- | -45.01 | 10.98 | -25.40 | -- | -- | -- |
| ExpreS2ion Biotech Holding AB | 755.60k | -8.24m | 6.42m | 28.00 | -- | 1.23 | -- | 8.49 | -2.12 | -2.12 | 0.1895 | 1.19 | 0.0832 | -- | 9.91 | -- | -90.72 | -64.80 | -113.72 | -77.46 | -109.74 | -1.94 | -1,090.91 | -532.25 | -- | -- | 0.0045 | -- | 43.07 | -0.1561 | 19.07 | -- | 19.90 | -- |
| Cannabis Poland SA | 46.22k | -156.23k | 6.53m | -- | -- | 51.85 | -- | 141.26 | -0.0255 | -0.0255 | 0.0076 | 0.0111 | 0.3018 | 0.8264 | 5.07 | -- | -102.76 | -116.92 | -175.94 | -136.30 | 26.16 | 12.29 | -340.53 | -959.39 | 1.35 | -45.88 | 0.2547 | -- | -47.55 | 50.23 | 14.30 | -- | -- | -- |
| Spago Nanomedical AB (publ) | 103.31k | -3.63m | 6.58m | 13.00 | -- | 1.81 | -- | 63.70 | -0.3818 | -0.3818 | 0.0115 | 0.1882 | 0.0093 | -- | 5.74 | 92,538.46 | -32.61 | -20.19 | -35.38 | -20.97 | 247.55 | -- | -3,509.81 | -4,853.45 | -- | -- | -- | -- | 14.14 | -- | -7.72 | -- | -- | -- |
| Prolight Diagnostics AB (publ) | 0.00 | -2.38m | 6.70m | -- | -- | 0.2246 | -- | -- | -0.0984 | -0.0984 | 0.00 | 0.6946 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -13.84 | -- |
| Evolva Holding Ltd | 4.27m | -103.87m | 6.71m | 49.00 | -- | 1.17 | -- | 1.57 | -14.04 | -14.04 | 0.7083 | 0.77 | 0.0685 | -- | 1.91 | -- | -166.87 | -37.51 | -190.97 | -41.07 | -23.54 | -- | -2,434.99 | -818.05 | -- | 0.4155 | 0.00 | -- | 517.55 | -14.19 | -22.13 | -- | -- | -- |
| Plus Therapeutics Inc | 9.88m | -25.56m | 7.15m | 20.00 | -- | 0.00 | -- | 0.7243 | -3,070,823.00 | -3,070,823.00 | 987,822.20 | 2,126,137.00 | 0.2333 | 1.31 | 5.74 | 79,663.08 | -60.36 | -93.65 | -78.90 | -129.83 | 63.23 | 46.26 | -258.72 | -291.97 | 4.20 | -28.30 | 0.4628 | -- | -27.85 | 12.09 | -18.43 | -- | -19.87 | -- |
| Immunovia AB (publ) | 104.08k | -22.39m | 7.24m | 11.00 | -- | 1.93 | -- | 69.58 | -6.06 | -6.06 | 0.0276 | 0.9648 | 0.0075 | 58.23 | 14.96 | 110,181.80 | -160.93 | -41.33 | -194.89 | -44.24 | -5,523.76 | -7,553.76 | -21,512.13 | -20,879.29 | 2.03 | -- | 0.1675 | -- | 37.55 | 36.48 | -84.09 | -- | -50.93 | -- |
| Bioextrax AB publ | 176.64k | -1.85m | 7.41m | -- | -- | 3.60 | -- | 41.96 | -0.8026 | -0.8026 | 0.0769 | 0.6968 | 0.0681 | -- | 124.67 | -- | -71.18 | -86.39 | -82.24 | -110.84 | 34.95 | -- | -1,045.55 | -2,119.90 | -- | -- | -- | -- | 420.51 | 24.40 | -15.21 | -- | 56.86 | -- |
| Friulchem SpA | 26.66m | -299.00k | 7.52m | 86.00 | -- | 0.5384 | 15.35 | 0.2821 | -0.0498 | -0.0498 | 4.44 | 1.75 | 0.7064 | 2.93 | 4.28 | -- | -0.9831 | -0.3406 | -1.82 | -0.5598 | 18.17 | 17.60 | -1.39 | -0.4058 | 0.6212 | 0.6976 | 0.5576 | -- | -22.20 | 10.62 | -992.27 | -- | -- | -- |
| Cizzle Biotechnology Holdings PLC | 0.00 | -2.00m | 7.63m | 67.00 | -- | 3.98 | -- | -- | -0.0048 | -0.0048 | 0.00 | 0.0041 | 0.00 | -- | -- | -- | -76.69 | -144.15 | -82.81 | -167.75 | -- | -- | -- | -- | -- | -0.805 | 0.00 | -- | -- | -- | -88.27 | -- | -- | -- |
| Dextech Medical AB | 0.00 | -392.57k | 7.91m | 1.00 | -- | 2.85 | -- | -- | -0.2473 | -0.2473 | 0.00 | 1.75 | 0.00 | -- | -- | -- | -13.04 | -28.96 | -13.21 | -29.94 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 12.89 | -- | 0.412 | -- |
| Ziccum AB | 321.77k | -1.84m | 7.92m | 8.00 | -- | 9.69 | -- | 24.62 | -1.54 | -1.54 | 0.2701 | 0.6191 | 0.1553 | -- | 2.01 | 468,375.00 | -88.74 | -68.51 | -109.73 | -76.47 | -- | -- | -571.44 | -2,598.03 | -- | -- | 0.0908 | -- | -- | 75.20 | 25.62 | -- | -13.45 | -- |
Data as of May 03 2024. Currency figures normalised to Plus Therapeutics Inc's reporting currency: Euro EUR
